Rosuvamibe 10/10

ApprovedSmall molecule

Rosuvamibe 10/10 is one of 7 small molecule programs targeting Left ventricular diastolic dysfunction. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Left Ventricular Diastolic DysfunctionActive, not recruiting

Left Ventricular Diastolic DysfunctionApproved

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Left Ventricular Diastolic Dysfunction

#DrugCompanyPhaseTrials

Uloric

Takeda

Approved

1 2

Natrecor

SScios, Inc.

Approved

—3

Tenelia

Tanabe Pharma Corporation

Approved

1 4

Benzbromarone

AstraZeneca

Approved

1 5

Adempas

Bayer

Phase 2

1 6

Rosuvastatin 20

YYonsei University

Approved

1 7

Rosuvamibe 10/10

YYonsei University

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Left ventricular diastolic dysfunction1 trial

Compare the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Korean Patients With Left Ventricular Diastolic Dysfunction and Hyperlipidemia

Unknown status·YYonsei University·Phase 4·NCT04433533·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Rosuvamibe 10/10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rosuvamibe 10/10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rosuvamibe 10/10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: YYonsei University

Rosuvamibe 10/10

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Left ventricular diastolic dysfunction1 trial

References

Drug Info

Quick Facts

Related News